Latest Contracts News

Mach7 Technologies has been notified that the Veterans Health Administration will cease its NextGen PACS program, leading to a partial stop work order and cancellation of Phase 2 of the contract. Despite this, Mach7 remains focused on its broader commercial strategy.

Supply Network Limited has forecast a solid half-year profit of $22.9 million alongside a fully franked interim dividend of 36 cents per share, signalling steady performance in its supply chain operations.

ReadCloud Limited has secured over 50 new school contracts for 2026, driving strong growth in its VET-in-Schools and eBooks divisions despite ongoing funding challenges in its Industry Training segment.

Peak Processing has significantly expanded its manufacturing partnership with St. Peter’s Beverages, tripling its SKU production and boosting annual output by up to 700,000 units. This move strengthens its foothold in North America’s cannabis beverage market using proprietary technology.

Pure Foods Tasmania has launched contract manufacturing with Brilliant Food Australia, marking a significant step in utilising its Woodbridge Smokehouse facility and expanding regional employment.

Mayfield Group Holdings has acquired a strategic industrial property adjacent to its BE Switchcraft operations, enabling operational synergies and capacity expansion to support a $30 million contract pipeline.

Visionflex Group’s Q2 FY26 report reveals a 23% rise in annual recurring revenue and improved cash flow, even as overall revenue slips due to lower hardware sales.

Rhythm Biosciences has begun commercialising its blood-based colorectal cancer test, ColoSTAT®, following key accreditations and validation. The company also secured a strategic partnership with NHS England and expanded its geneType™ platform globally.

Celsius Resources has released a Definitive Feasibility Study for its Maalinao-Caigutan-Biyog (MCB) Copper-Gold Project, confirming robust economics and a 35-year mine life. The study highlights strong returns, low operating costs, and a clear path to development in the Philippines.

Cambium Bio has strengthened its financial footing with a $0.6 million R&D tax refund and a $2.4 million strategic placement, setting the stage for pivotal Phase 3 clinical trials of its lead ophthalmology candidate.

Nyrada Inc. has secured ethics approval to launch a Phase IIa clinical trial for its heart attack drug Xolatryp®, with patient recruitment set for March 2026. The company maintains a solid cash position of AU$7.12 million as it expands its research into oncology.

Arovella Therapeutics has filed an IND application for its lead CAR-iNKT therapy ALA-101, selected a CRO for its upcoming phase 1 trial, and secured $19.4 million in cash to fund clinical progress and pipeline expansion.